ReviewCancer metastasis reviews2026
Decoding osteosarcoma mechanobiology: PIEZO channels in tumor progression, immune remodeling, and pain.
Review in Cancer metastasis reviews, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteosarcoma arises in a mechanically active skeletal environment, but how physical cues shape tumor behavior, immunity, and pain remains poorly defined. This review examines PIEZO1 and PIEZO2 as compartment-specific mechanotransducers and distinguishes direct osteosarcoma evidence from disease-relevant preclinical findings and broader evidence from bone, immune, neural, and pain systems. PIEZO1 is best established in osteoblast-lineage cells and osteocytes, where it regulates bone remodeling and mechanical adaptation; its causal role in human osteosarcoma remains unresolved. In osteosarcoma models, PIEZO1-associated responses to stiffness and strain are linked to invasion, adhesion remodeling, YAP/TAZ signaling, and phenotypic plasticity. PIEZO2 is less well supported as a tumor-cell regulator and is more convincingly positioned in sensory neurons that mediate mechanically evoked bone cancer pain. PIEZO1 may also influence myeloid, dendritic-cell, and T-cell behavior, although this immune axis remains unvalidated in osteosarcoma. These compartment-specific roles expose a mechanotherapeutic paradox: pathways required for skeletal adaptation and repair may also be used by malignant or stromal compartments. Resolving this problem will require spatially resolved human studies, orthotopic immunocompetent models, and cell-type-selective perturbation.
Indexed as
Identifiers
42616189What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.